KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Expenses: 2010-2024

Historic Operating Expenses for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $580.2 million.

  • Supernus Pharmaceuticals' Operating Expenses rose 87.13% to $252.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $718.5 million, marking a year-over-year increase of 21.22%. This contributed to the annual value of $580.2 million for FY2024, which is 5.33% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Operating Expenses of $580.2 million as of FY2024, which was down 5.33% from $612.8 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Operating Expenses high stood at $621.1 million for FY2022, and its period low was $346.7 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $612.8 million (2023), whereas its average is $604.7 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 42.41% in 2021, then decreased by 5.33% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Operating Expenses (Yearly) stood at $346.7 million in 2020, then spiked by 42.41% to $493.7 million in 2021, then grew by 25.80% to $621.1 million in 2022, then dropped by 1.34% to $612.8 million in 2023, then decreased by 5.33% to $580.2 million in 2024.